Lim CH, Chen HH, Chen YH, Chen DY, Huang WN, Tsai JJ, Hsieh TY, Hsieh CW, Hung WT, Lin CT, Lai KL, Tang KT, Tseng CW, Chen YM*. The risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: a 15-year real world experience in Taiwan. PLOS ONE. 2017; 12:e0178035.
Chen YM, Huang WN, Wu YD, Lin CT, Chen YH, Chen DY, Hsieh TY. Reactivation of hepatitis B virus infection in rheumatoid arthritis patients receiving tofacitinib: a real-world study. Ann Rheum Dis. (Accepted)
Chuang HC, Chen YM, Hung WT, Li JP, Chen DY, Lan JL, Tan TH. Downregulation of the phosphatase JKAP/DUSP22 in T Cells as a potential new biomarker of systemic lupus erythematosus nephritis. Oncotarget. 2016; 7:57593-57605.（共同第一作者）
Chen YM, Lin CH, Lan TH, Chen HH, Chang SN, Chen YH, Wang JS, Hung WT, Lan JL, Chen DY. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study. Rheumatology (Oxford). 2015; 54:1244-1249.
Chen YM, Chen HH, Chen YH, Hsieh TY, Hsieh CW, Hung WT, Lan JL, Chen DY*. A comparison of safety profiles of tumour necrosis factor α inhibitors and rituximab therapy in patients with rheumatoid arthritis and chronic hepatitis C. Ann Rheum Dis. 2015; 74:626-627.
